unmet needs in nsclc that egfr inhibitor bdtx-1535 aims to address
Published 2 years ago • 159 plays • Length 4:04Download video MP4
Download video MP3
Similar videos
-
4:54
unmet needs in glioblastoma that egfr inhibitor bdtx-1535 aims to address
-
3:14
bdtx-1535: a novel treatment for egfr-mutated nsclc and glioblastoma
-
3:29
pre-clinical data for novel egfr inhibitor bdtx-1535
-
1:26
unmet needs in limited-stage small cell lung carcinoma
-
1:49
addressing unmet needs in patients with lung cancer
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
1:58
unmet needs in braf nsclc
-
3:28
the future of nsclc treatment
-
6:55
conclusion: addressing unmet needs in lung cancer
-
3:49
unmet needs: sequencing after immunotherapy in nsclc
-
1:06
unmet needs in scd: the need for improved therapies and combination approaches
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
11:22
addressing unmet needs for patients with resectable nsclc and the benefits of an mdt approach
-
2:10
unmet needs and role of immunotherapy in stage 3 nsclc
-
0:43
the unmet need in dlbcl
-
3:02
osimertinib for treating non-small cell lung cancer
-
1:45
how is non-small cell lung cancer (nsclc) diagnosed?
-
1:47
dr. bunn on tmb as a biomarker in small cell lung cancer